drugset / Trial / NCT02237534

Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia

NCT02237534

Phase 4 Unknown 60 enrolled Osaka University Bayer · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the effect of lanthanum carbonate and calcium carbonate on the progression of coronary calcification and vascular endothelial dysfunction.

Timeline

Start
2014-09
Primary completion
2023-03-31
Completion
2023-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Calcium carbonate Other / unclassified 1500 mg
Subject Lanthanum Carbonate Other / unclassified 750 mg